SCHEMBL19204498

SCHEMBL19204498

O=c1c(O)c(-c2ccc(O)c(O[PH](=O)O)c2)oc2cc(O)cc(O)c12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 8/20 0.73
MEN1 O00255 7/20 0.73
KMT2A Q03164 7/20 0.73
CYP1A1 P04798 7/20 0.73
CYP1B1 Q16678 7/20 0.73
XDH P47989 5/20 0.73
CA12 O43570 4/20 0.73
PPARG P37231 4/20 0.73
CA7 P43166 4/20 0.73
IPMK Q8NFU5 4/20 0.73
IP6K2 Q9UHH9 4/20 0.73
CA2 P00918 3/20 0.73
CA4 P22748 3/20 0.73
BCL9 O00512 9/20 0.67
CTNNB1 P35222 9/20 0.67
ABCB1 P08183 7/20 0.67
CYP3A4 P08684 5/20 0.67
CYP2C9 P11712 5/20 0.67
FTO Q9C0B1 5/20 0.67
KDM4E B2RXH2 4/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3757879 0.88 CYP1A2 (0.76) CYP1A2MEN1KMT2ACYP1A1CYP1B1
Isorhamnetin SCHEMBL19235 0.84 MEN1 (1.00) CYP1A2MEN1KMT2ACYP1A1CYP1B1
Isorhamnetin SCHEMBL30385934 0.84 MEN1 (1.00) CYP1A2MEN1KMT2ACYP1A1CYP1B1
Isorhamnetin SCHEMBL29390102 0.84 MEN1 (1.00) CYP1A2MEN1KMT2ACYP1A1CYP1B1
Isorhamnetin SCHEMBL29377152 0.84 MEN1 (1.00) CYP1A2MEN1KMT2ACYP1A1CYP1B1
SCHEMBL18102793 0.83 MEN1 (0.76) CYP1A2MEN1KMT2ACYP1A1CYP1B1
Quercetin SCHEMBL28512957 0.82 MEN1 (0.97) CYP1A2MEN1KMT2ACYP1A1CYP1B1
SCHEMBL6122891 0.82 CYP1A2 (0.74) CYP1A2MEN1KMT2ACYP1A1CYP1B1
SCHEMBL16984539 0.82 MEN1 (0.74) CYP1A2MEN1KMT2ACYP1A1CYP1B1
Quercetin-3'-O-Phosphate SCHEMBL118113 0.81 CYP1A2 (0.73) CYP1A2MEN1KMT2ACYP1A1CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170216286-A1 KILLING SENESCENT CELLS AND TREATING SENESCENCE-ASSOCIATED CONDITIONS USING A SRC INHIBITOR AND A FLAVONOID MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2017-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170216286-A1 KILLING SENESCENT CELLS AND TREATING SENESCENCE-ASSOCIATED CONDITIONS USING A SRC INHIBITOR AND A FLAVONOID SRC, TP53, LIMS1 CYP1A2 3742/4885MEN1 3132/4885KMT2A 1980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.